CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market to grow by USD 2.23 billion between 2023 and 2028, growth Driven by High target affinity and specificity of CTLA4 inhibitors - Technavio
The expansion of research indications of CTLA4 is a major trend in the market
NEW YORK, Jan. 25, 2024 /PRNewswire/ -- The CTLA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market is estimated to grow by USD 2.23 billion from 2023 to 2028, growing at a CAGR of 15.11%. High target affinity and specificity of CTLA4 inhibitors are notably driving the growth. Despite several approved therapies, the treatment landscape for advanced or recurrent cancer lacks sufficient drug responsiveness. Available therapies often lead to severe side effects, reducing patient compliance. Chemotherapy, the current standard of care for advanced cancers, causes significant adverse effects like bone marrow suppression, diarrhea, and hair loss. Similarly, surgery and radiation therapy have limitations in treating recurring carcinomas like melanomas. Furthermore, CTLA4 inhibitors work by enhancing the immune system, resulting in comparatively fewer associated side effects than traditional oncology treatments.
The expansion of research indications of CTLA4 is expected to open multiple growth opportunities for players. However, the stringent regulations in manufacturing CTLA4 inhibitors might impact the business of companies during the forecast period.
The CTLA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market report provides complete insights on key companies including AstraZeneca Plc, Bio Techne Corp., BioNTech SE, Bristol Myers Squibb Co., HBM Holdings Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Xencor Inc., Agenus Inc., Akeso Inc., Innovent Biologics Inc., Molecular Templates Inc., TRACON Pharmaceuticals Inc., and XILIO THERAPEUTICS INC..
The report includes a competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score and market performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Based on Type, the market is classified into monotherapy and combination therapy. The monotherapy segment is estimated to witness significant growth during the forecast period. Monotherapy involves using a single drug to treat a disease or condition. Typically, it represents the smaller segment, as combined drugs are favored due to their ability to target the condition using multiple drugs. Additionally, monotherapy is initially less expensive compared to combination therapy.
Based on Geography, the market is classified as North America, Europe, Asia, and the Rest of the World (ROW). North America is estimated to contribute 57% to the growth during the forecast period. The growth and trends of the CTLA4 inhibitors market in the region are mainly fueled by the sales of the approved CTLA4 inhibitor YERVOY and the rising incidence of various cancer types like melanomas and NSCLC. Cancer ranks among the most prevalent chronic illnesses in the US, necessitating advanced and specialized treatments. Targeted therapies like CTLA4 inhibitors have the potential to address this need.
Applications of CTLA4 (Cytotoxic T-lymphocyte-associated protein 4) Inhibitors in Immuno-Oncology
CTLA4 (Cytotoxic T-lymphocyte-associated protein 4) inhibitors, such as ipilimumab (Yervoy), are a key component of immuno-oncology and cancer immunotherapy. These inhibitors, often used in combination therapies with PD-1/PD-L1 inhibitors, have shown promise in clinical trials for melanoma treatment and other oncological diseases. Their mechanism involves immune checkpoint blockade, and they are classified as oncology pharmaceuticals and biologic therapeutics. FDA approvals, adverse effects, market growth, patent expiry, and the involvement of Bristol-Myers Squibb (BMS) in research and development are key factors in this field. Other considerations include healthcare reimbursement, regulatory policies, pharmaceutical licensing, personalized medicine, clinical outcomes, competition, and the role of biotechnology companies, treatment guidelines, health economics, and patient advocacy groups in shaping the landscape of CTLA4 inhibitors. Emerging markets also play a role in the expansion of these therapies.
Related Report
The global proteasome inhibitors market size is estimated to grow by USD 2.91 billion at a CAGR of 7.48% between 2023 and 2028.
The HDAC (histone deacetylase) inhibitors market is estimated to grow at a CAGR of 7.73% between 2022 and 2027. The size of the market is forecast to increase by USD 172.61 million.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Sizes
Five Forces Analysis
Segmentation by Distribution Channel
Segmentation by Type
Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About US
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging trends and provide actionable insights to help businesses identify opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable insights to identify opportunities in existing and potential markets and assess their competitive positions within changing scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
Share this article